# FM 140 vs FM100 Study in Patients With Multiple Myeloma

> **NCT00505895** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 52 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Fludarabine
- **PROCEDURE:** Stem Cell Infusion
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00505895
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505895, "FM 140 vs FM100 Study in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00505895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*